Video

Looking Ahead at Clinical Trial Metrics for Plaque Psoriasis

Author(s):

Brad Glick, DO, MPH,George Han, MD, PhD

Dermatology experts discuss looking ahead at clinical trial metrics and how to make different outcomes more highlighted to overcome challenges in plaque psoriasis.

Related Videos
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
Melodie Young, ASN, RN: Updates on Therapies for Pediatric Patients with Psoriasis, PsA
Harnessing Patient Insights: The Role of PROs in Managing Psoriasis and Psoriatic Arthritis
Melinda Gooderham, MD: What Do the New Roflumilast Foam Data Mean for Psoriasis Patients?
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Related Content
Study Highlights Impact of Smoking on Surgical Outcomes for HS
December 20th 2024

Study Highlights Impact of Smoking on Surgical Outcomes for HS

Tim Smith
MEDcast logo
June 26th 2024

Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis

Linda Stein Gold, MD Bruce Strober, MD, PhD, FAAD
Psoriasis Study Identifies Strategies for Enrolling More Patients with Skin of Color
December 19th 2024

Psoriasis Study Identifies Strategies for Enrolling More Patients with Skin of Color

Tim Smith
A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis
February 28th 2024

A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis

Lauren Miller, MPAS, PA-C Jayme M Heim, MSN, FNP-BC Terry Faleye, MPAS, PA-C
Deaucravacitinib Safe, Effective Through 3 Years for Patients with Psoriasis
December 4th 2024

Deucravacitinib Safe, Effective Through 3 Years for Patients with Psoriasis

Tim Smith
FDA Receives sBLA for Guselkumab Treatment of Psoriasis, Juvenile PsA in Adolescents
December 2nd 2024

FDA Receives sBLA for Guselkumab Treatment of Psoriasis, Juvenile PsA in Adolescents

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.